Rituximab and lenalidomide for the treatment of relapsed or refractory indolent non-Hodgkin lymphoma: real-life experience.

Haematologica · 2025 · PMC11788635 · PMID 39234863

Europe PMC DOI

hedged sentences

0.1000

closest p · 2.0× alpha

0.4000

boldest claim

The sentences

showed a trendP =0.1so close (0.05 < p ≤ 0.1)

Likewise, harboring bulky disease showed a trend towards a lower likelihood of achieving a CR in MZL patients ( P =0.1; Online Supplementary Table S1 ).

also in 53,322 other papers

did not reach statistical significanceP =0.4not close (p > 0.1)

When restricting the analysis to the 23 FL patients who received R-len as second line treatment, individuals with POD24 (N=14) exhibited a shorter mPFS (26 months; 95% CI: 14-NR) than non-POD24 patients (45 months; 95% CI: 28-NR), though this difference did not reach statistical significance ( P =0.4).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.